PRECIGEN, INC. Payment for Debt Extinguishment or Debt Prepayment Cost
PRECIGEN, INC. (PGEN) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $120.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2026-03-25
- PRECIGEN, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2023-12-31 was $0.00.
- PRECIGEN, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2023-09-30 was $0.00.
- PRECIGEN, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2023-06-30 was $63.00K.
- PRECIGEN, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2023-03-31 was $57.00K.
- PRECIGEN, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $120.00K, a 79.59% decline from fiscal 2022.
- PRECIGEN, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2022 was $588.00K.
- PRECIGEN, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2021 was $0.00.
- PRECIGEN, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2020 was $0.00.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $63.00K derived: sum of 3 quarters · filed 2026-03-25 | $120.00K 10-K · filed 2026-03-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $63.00K derived: sum of 2 quarters · filed 2024-11-14 | $120.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $120.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $57.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $588.00K 10-K · filed 2025-03-19 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-06 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |